Case Report: Early Association of Vemurafenib to Standard Chemotherapy in Multisystem Langerhans Cell Histiocytosis in a Newborn: Taking a Chance for a Better Outcome?

Stefania Gaspari*, Valentina Di Ruscio, Francesca Stocchi, Roberto Carta, Marco Becilli and Maria Antonietta De Ioris

Department of Hematology/Oncology, Cell and Gene Therapy, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Bambino Gesù Children’s Hospital, Rome, Italy

Langerhans cell histiocytosis (LCH) is due to aberrant monoclonal proliferation and accumulation of dendritic cells, ranging from a self-limiting local condition to a rapidly progressive multisystem disease with poor prognosis. Pathogenic cells originate from a myeloid-derived precursor characterized by an activation of the MAPK/ERK signaling pathway in about 70% of cases. In particular, BRAF V600E mutation is usually associated with a more severe clinical course and poor response to chemotherapy. We report on a newborn with multisystem LCH in life-threatening medical conditions. At diagnosis, the patient was successfully treated with the early association of BRAF inhibitor Vemurafenib to standard chemotherapy representing a new approach in first-line treatment. A rapid clinical improvement with a prompt fever regression from day 2 and complete resolution of skin lesions by week 2 were observed; laboratory data normalized as well. Vemurafenib was discontinued after 12 months of treatment. No signs of relapse occurred after 12 months of discontinuation. This case indicates that early combination of target therapy with standard treatment may induce rapid response and prolonged disease remission without significant toxicities in infants. This approach represents a valid and safe option as first-line treatment in multisystem disease, especially in high-risk patients.

Keywords: target therapy, Langerhans cell histiocytosis, Vemurafenib, multisystem disease, newborn

INTRODUCTION

Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasm, with an incidence ranging from 2.6 to 8.9 cases per million in children under the age of 15 years with a mean age at diagnosis of approximately 3 years (1, 2). LCH is characterized by clonal infiltrating pathological proliferation of CD1a+/CD207+ dendritic cells, spanning from a self-limiting local condition to a rapidly progressive multisystem disease with poor prognosis (3).
Treatment varies greatly depending on the involved organs (4). A watch-and-wait strategy may be appropriate for single-organ disease. A surgical approach is the current option for isolated bone involvement. Skin lesions may resolve spontaneously or may need topical steroids, oral methotrexate, or thalidomide (5). These patients with localized disease usually have an excellent event-free survival (EFS) and overall survival (OS) of 80.6% and 100%, respectively (6, 7).

Multisystem disease (MS) is classified according to the presence of risk organs (RO) involvement, including the hematopoietic system, spleen, and/or liver (4).

Treatment with prednisone and vinblastine, according to LCH IV Protocol (8), represents the standard of care of MS-LCH with a 10-year OS and EFS rates of 49% and 79%, respectively (7, 9, 10). Several studies demonstrated that OS is significantly lower among patients younger than 2 years of age, who frequently show a RO involvement, elevated inflammatory markers, and resistance to standard treatment regimens (11–13). Refractory LCH is usually treated with highly toxic second-line chemotherapy (including cytarabine and vincristine or cladribine) or hematopoietic stem cell transplantation (HSCT).

According to recent molecular findings, a targeted therapy is proposed in high-risk pediatric patients, especially with RO pattern, who fail standard therapy or experience multiple relapses. Recurrent BRAFV600E mutations have been identified in approximately 60% of LCH patients (14), changing the natural history of the disease. In fact, it is widely known that BRAF gene controls the production of BRAF protein, which is part of a signaling pathway known as the RAS/MAPK pathway, which regulates cell proliferation, differentiation, migration, and apoptosis (14, 15). In the presence of BRAF mutations, the BRAF-mutated protein provides continuous signal to the nucleus and allows uncontrolled growth and differentiation of Langerhans cells (16). Other gene mutations, such as that involving the MAP2K gene and other rarer genes (such as ARAF), have also been described (17).

The identification of BRAF mutation has led to the promising therapeutic approach based on the BRAF inhibitor Vemurafenib (18–20) in particular for infants with MS disease. However, it is known that it failed to eradicate neoplastic clone and to maintain long-term disease remission (21).

In this report, we describe a newborn with MS-LCH diagnosed in life-threatening medical conditions successfully treated since diagnosis with Vemurafenib in combination with standard treatment, with no sign of disease relapse several months after BRAF inhibitor discontinuation.

CASE DESCRIPTION

A 20-day male was referred to primary neonatal intensive care unit in critical conditions with persistent fever, enlarged abdomen, generalized crusted skin purpuric lesions, increased inflammatory markers associated with diarrhea since first days of life, and anasarca. He was born at 37 weeks after a normal pregnancy and, soon after birth, he presented diffuse multiple purpuric lesions. The child needed non-invasive respiratory support with Continuous Positive Airway Pressure (CPAP) and parenteral nutrition. The chest computed tomography (CT) showed multiple bilateral nodules associated with air-space consolidation. Two sets of blood culture specimens were drawn, which yielded Candida albicans.

Clinical examination revealed a purpuric disseminated rash (Figure 1), cervical lymphadenopathy, and hepatosplenomegaly. Laboratory findings demonstrated anemia (hemoglobin 7.9 g/dl), thrombocytopenia (26,000/mm³), elevated C-reactive protein.

![Figure 1](https://www.frontiersin.org/articles/10.3389/fonc.2021.794498/medias/upl/ds/00020.jpg)

**Figure 1** | Skin response (A, B) skin at diagnosis, (C) skin after 2 week of vemurafenib treatment, (D) skin after 1 month of vemurafenib treatment.
(11.70 mg/dl), hyperbilirubinemia (total bilirubin 3.07 mg/dl, direct 1.56 mg/dl), with low total protein (3.5 g/dl) and albumin (1.9 g/dl). The child required platelet support almost daily and blood transfusion regularly.

Imaging findings, namely, abdominal ultrasonography and CT scan, revealed hepatomegaly and splenomegaly without focal lesions, as well as multiple bilateral lymphadenopathies in the abdomen and in the thorax.

Magnetic resonance imaging (MRI) of the brain excluded active lesions involving the hypothalamic–pituitary axis, space-occupying lesions, and neurodegenerative lesions of the cerebellum, pons, brainstem, basal ganglia, and gray or white matter of the brain.

Based on the clinical history and laboratory data, a diagnosis of LCH was suspected and confirmed by skin biopsy. The pathology examination revealed multiple aggregates of cells with eosinophilic cytoplasm and nucleus with irregular bland chromatin. CD1a, Langherin, S100, BRAF, and ALKp80 were positive at immunohistochemistry.

A bone marrow biopsy was also obtained, which demonstrated infiltrations of CD1a and CD207-positive histiocytes.

LCH with a multisystem involvement—liver, spleen, bone marrow, lymph nodes, bowel, and skin—was diagnosed with a BRAFV600E mutation detected by immunohistochemical and molecular analysis.

Considering the life-threatening conditions and the concomitant sepsis due to an opportunistic agent (Candida sepsis), after obtaining parent’s informed consent, the patient started Vemurafenib at a dose of 10 mg/kg twice a day, and after 1 week, the standard treatment with prednisone and vinblastine according to LCH IV Protocol (8) was applied (see Figure 2).

After taking Vemurafenib, the patient experienced rapid clinical improvement with prompt fever regression from day 2 and complete resolution of skin lesions by the second week. Within several days, splenomegaly and lymphadenopathies disappeared, liver function normalized, and no further albumin infusions were required. The patient resumed breastfeeding and gradually gained weight; parenteral nutrition support was discontinued on day 10. Blood counts normalized without need of blood-derived products support starting from day 8 (see Figure 2).

According to protocol guidelines, chemotherapy with vinblastine and prednisone was administered weekly for the first 12 weeks and then every 3 weeks, without major toxicity. No infectious complications or organ toxicities were recorded. After 12 months of treatment, Vemurafenib was discontinued safely, without disease recurrence. At the last follow up, 24 months after diagnosis, the patient is in good clinical condition and complete remission, with weight and length at the 75th percentile for age.

DISCUSSION

This is the first report on early administration of the BRAF inhibitor Vemurafenib as a front-line treatment in combination with standard chemotherapy in a newborn with MS-LCH. To the best of our knowledge, Vemurafenib has been employed only in second- or third-line treatment (21–23).

A newborn with severe MS disease and in poor clinical condition represents a critical emergency situation that did not allow us to start chemotherapy treatment safely, also considering the recent history of Candida sepsis. The target therapy with Vemurafenib resulted in a brilliant clinical response with fever regression, rapid improvement of skin lesions, and normalization of biological markers of systemic inflammation.

The discovery of recurrent BRAF mutations is a real breakthrough in understanding LCH pathogenesis (12, 14), with the possibility of selective inhibition of the BRAF kinase (22, 24, 25).

In relapsed/refractory LCH, Vemurafenib alone is able to induce either complete or partial response in 70% and 30% of children, respectively, with less toxicities than cladribine, cytarabine, or allogeneic HSCT, a procedure that represents the current standard treatment for refractory LCH. Despite the high rate of response associated with the use of Vemurafenib, a high proportion of disease relapse is reported after drug discontinuation (23).

Heritier et al. first reported an 8-month-old infant with multisystem-resistant LCH receiving Vemurafenib for a 3-month period as a second-line treatment. Thereby, 2 months
after discontinuation, a skin relapse was detected and Vemurafenib was resumed (2.4).

In our case, Vemurafenib was administered at diagnosis as a front-line, single-agent treatment, resulting in prompt reduction of disease burden and clinical and biological response. The combination of Vemurafenib with LCH standard chemotherapy after the first week, never reported before, was well tolerated, and caused no major side effects. In order to prevent disease reactivation, BRAF inhibitor and vinblastine were maintained for a 12-month period. After a follow-up of 12 months from Vemurafenib discontinuation, the patient is in good clinical condition (Lansky scale 100% and at 75th centile for length and weight) and in complete remission with no signs of disease recurrence.

In conclusion, our case demonstrates that the early combination of target therapy with standard chemotherapy is effective in inducing a prompt response and prolonged disease remission with no toxicities. Therefore, we suggest that target therapy associated with standard treatment may be considered as a valid and safe option in first-line treatment in multisystem disease, especially in high-risk patients. Moreover, it should represent a promising option in infants reducing the chemotherapy use. Prospective trials are warranted to evaluate the effectiveness and the safety of BRAF inhibitor in combination with standard treatment as front-line therapy.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS
All the authors took care of the patient. All authors contributed to the article and approved the submitted version.

REFERENCES
1. Haroche J, Cohen-Aubart F, Rollins BJ, Donadieu J, Charlotte F, Idbaït A, et al. Histiocytes: Emerging Neoplasia Behind Inflammation. *Lancet Oncol* (2017) 18(2):e113–25. doi: 10.1016/S1470-2045(17)30031-1
2. Stalemark H, Laurencikas E, Karis J, Gavhed D, Fadel B, Henter J. Incidence of Langerhans Cell Histiocytosis in Children: A Population-Based Study. *Pediatr Blood Cancer* (2008) 51(1):76–81. doi: 10.1002/pbc.21504
3. Egeler RM, Katwa S, Leenen PJ, Beverley P, Collin M, Gunhoux F, et al. Langerhans Cell Histiocytosis is a Neoplasm and Consequently its Recurrence is a Relapse: In Memory of Bob Arceci. *Pediatr Blood Cancer* (2016) 63:1704–12. doi: 10.1002/pbc.26104
4. Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, et al. Langerhans Cell Histiocytosis (LCH): Guidelines for Diagnosis, Clinical Work-Up, and Treatment for Patients Till the Age of 18 Years. *Pediatr Blood Cancer* (2013) 60(2):175–84. doi: 10.1002/pbc.23467
5. Krafchik B, Pope E, Walsh SRA. Histiocytosis of the Skin in Children and Adults. In: S Weitzman, M Egeler, editors. *Histiocytosis Disorders of Children and Adults*. Cambridge, UK: Cambridge University Press (2005). p. 130–53.
6. Gadenr H, Minkov M, Grois N, Pütchger U, Thiem E, Arioi M, et al. Therapy Prolongation Improves Outcome in Multisystem Langerhans Cell Histiocytosis. *Blood* (2013) 121:5006–5014. doi: 10.1182/blood-2012-09-455774
7. Tzotzola V, Petrikos L, Papadakis V, Mitropoulou G, Kelaidi C, Dimitriadis E, et al. Long-Term Outcome, Clinical Course and Treatment Approaches of Paediatric Langerhans Cell Histiocytosis: A Greek Reference Centre Report. *Acta Paediatr* (2021) 110(6):1944–51. doi: 10.1111/apa.15743
8. LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with LANGERHANS CELL HISTIOCYTOSIS. *EurAaCRT Nr.: 2012-004914-32 International Sponsor: Childrens Cancer Research Institute. Vienna (2011). Austria Protocol Version 1.0, April 13th.
9. Tuyuz G, Yildiz I, Ozdemir N, Adalatli I, Kurugolgu S, Apak H, et al. Langerhans Cell Histiocytosis: Single Centre Experience of 25 Years. *Mediterr J Hematol Infect Dis* (2011) 3:190035. doi: 10.4084/MJHID.2011.035
10. Kim B, Koh KN, Shu I, Song JS, Lee JW, Kang HH, et al. Korea Histiocytosis Working Party. Clinical Features and Treatment Outcomes of Langerhans Cell Histiocytosis: A Nationwide Survey From Korea Histiocytosis Working Party. *J Pediatr Hematol Oncol* (2014) 36(2):125–33. doi: 10.1097/MPH.0000000000000054
11. Bhatia P, Singh M, Sharma M, Sharma A, Kakkar N, Radhika S, et al. BRAF V600E Mutation in Childhood Langerhans Cell Histiocytosis Correlates With Multisystem Disease and Poor Survival. *Blood Cells Mol Dis* (2020) 82:102356. doi: 10.1016/j.bcmd.2019.102356
12. Berros ML, Lim KP, Peters T, Price J, Takizawa H, Salomon H, et al. BRAF-V600E Expression in Precursor Versus Differentiated Dendritic Cells Defines Clinically Distinct LCH Risk Groups. *J Exp Med* (2014) 211:669–83. doi: 10.1084/jem.20130977
13. Heritier S, Emile JF, Barkaoui MA, Thomas C, Fraigat S, Boudjemaa S, et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. *J Clin Oncol* (2016) 34:3023–30. doi: 10.1200/JCO.2015.65.9508
14. Badalain-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. BRAF Mutations and Changes in Treatment Strategies in Langerhans Cell Histiocytosis. *Blood* (2010) 116(11):1919–23. doi: 10.1182/blood-2010-04-279083
15. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, et al. Mutually Exclusive Recurrent Somatic Mutations in MAP2K1 and BRAF Support a Central Role for ERK Activation in LCH Pathogenesis. *Blood* (2014) 124(19):3007–15. doi: 10.1182/blood-2014-05-577825
16. Bubolz AM, Weissinger SE, Stenzinger A, Arndt A, Steineckl K, Bruderlein S, et al. Potential Clinical Implications of BRAF Mutations in Histiocytic Proliferations. *Oncotarget* (2014) 5:4060–70. doi: 10.18632/oncotarget.2061
17. Nelson DS, Quispel W, Badalain-Very G, van Halteren AG, van den Bos C, Bovée JV, et al. Somatic Activating ARAF Mutations in Langerhans Histiocytosis. *Blood* (2014) 123(20):3152–5. doi: 10.1182/blood-2013-06-51139
18. Charles J, Bajani JC, Fiandrino G, Busser B. Major Response to Vemurafenib in Patient With Severe Cutaneous Langerhans Cell Histiocytosis Harboring BRAF V600E Mutation. *J Am Acad Dermatol* (2014) 71:e97–99. doi: 10.1016/j.jaad.2014.03.038
19. Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-Label VE-BASKET Study. *JAMA Oncol* (2018) 4:384–8. doi: 10.1001/jamaoncol.2017.5029
20. Kolenova A, Schwentner R, Jug G, Simonitsch-Klupp I, Kornauth C, Plank L, et al. Targeted Inhibition of the MAP2K1 Pathway: Emerging Salvage Option for Progressive Life-Threatening Multisystem LCH. *Blood Adv* (2017) 1:352–6. doi: 10.1182/bloodadvances.2016003533
21. Gandolfi L, Adamo S, Pileri A, Broccoli A, Argnani L, Zinzani PL, Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor. *J Natl Compr Canc Netw* (2015) 13:715–8. doi: 10.6004/jnccn.2015.0086
22. Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. *J Clin Oncol* (2019) 37(31):2857–65. doi: 10.1200/JCO.2019.00456
23. Heissig A, Sörensen J, Zimmermann SY, Schönig S, Schwabe D, Kvasnicka HM, et al. Vemurafenib in Langerhans Cell Histiocytosis: Report of a Pediatric
Patient and Review of the Literature. *Oncotarget* (2018) 9(31):22236–40. doi: 10.18632/oncotarget.25277

24. Heritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. *JAMA Oncol* (2015) 1:836–8. doi: 10.1001/jamaoncol.2015.0736

25. Hutter C, Minkov M. Insights Into the Pathogenesis of Langerhans Cell Histiocytosis: The Development of Targeted Therapies. *Immunotargets Ther* (2016) 5:81–9. doi: 10.2147/ITT.S91058

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Gaspari, Di Ruscio, Stocchi, Becilli and De Ioris. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.